Feedback
We’d love to hear your feedback on this activity. It helps us to continually improve our products.
CORRECT!
Faculty & Disclosures
Prof. Aleš Linhart
Charles University and General University Hospital, Prague, Czech Republic
Prof. Aleš Linhart, DSc, FESC, currently heads the Department of Cardiovascular Medicine at the First Medical Faculty and General University Hospital in Prague, Czech Republic. He serves as vice-dean for international affairs at the First Faculty of Medicine of Charles University in Prague. read more
Prof. Linhart obtained his medical degree at Charles University, and received his training in cardiology and vascular medicine at General University Hospital and Broussais Hospital in Paris, France.
In 2004 he was appointed professor at Charles University. His research focuses mainly on Fabry disease, metabolic cardiomyopathies, noninvasive cardiac imaging, and atherosclerosis. He is a member of several scientific societies, including the Czech Society of Cardiology and the European Society of Cardiology (ESC).
Prof. Linhart served as the chairman of the Working Group on Myocardial and Pericardial Diseases of the ESC and is the immediate past-president of the Czech Society of Cardiology. He has authored or co-authored more than 450 scientific peer-reviewed papers, 85 book chapters, and three monographs.
Prof. Aleš Linhart discloses: Advisory board and panel fees from Chiesi and Sanofi. Consultant fees from 4D Molecular Therapeutics, Amicus Therapeutics, Chiesi and Sanofi (relationship terminated). Grants/research support from Sanofi. Other financial or material support (royalties, patent, etc.) from Takeda (relationship terminated). Speaker’s Bureau fees from Amicus Therapeutics, Chiesi, Sanofi and Takeda.
Dr Eric Wallace
University of Alabama at Birmingham School of Medicine, Birmingham, AL, USA
Dr Wallace is a practising nephrologist and professor of medicine at the University of Alabama at Birmingham (UAB) School of Medicine in the USA, where he directs the UAB Rare Genetic Disease Clinic with a focus on Fabry disease. read more
He became the medical director of telehealth for UAB in January 2017, given his work on telehealth for home dialysis in patients with rare diseases.
Dr Wallace has earned numerous accolades, including the American Society of Nephrology Mid-Career Award. He has served as the principal investigator in numerous studies and clinical trials in Fabry disease. It is his goal to improve access to rare disease care across the USA by adding to the body of knowledge needed to treat patients and improving their access to care with telehealth.
Dr Eric Wallace discloses: Advisory board or panel fees from Sanofi. Consultant fees from Amicus Therapeutics, Chiesi, Sanofi and Walking Fish Therapeutics. Other financial or material support (principal/sub investigator fees for sponsored clinical studies) from Natera and Sanofi.
Prof. William Wilcox
Emory University School of Medicine, Atlanta, GA, USA
Prof. William Wilcox is a clinical, biochemical, and molecular geneticist in the Division of Medical Genetics at the Emory University School of Medicine in the USA. read more
He specializes in the diagnosis and treatment of metabolic disorders and genetic disorders of the skeleton, particularly dwarfisms and limb deficiency disorders.
Prof. Wilcox trained in paediatrics at the University of California, Los Angeles (UCLA) and then medical genetics in the UCLA Intercampus Medical Genetics Training Program. He was then a member of the UCLA paediatrics faculty based in the Medical Genetics Institute at Cedars-Sinai Medical Center in Los Angeles, until relocating to Emory in 2014.
Prof. William Wilcox discloses: Advisory board or panel fees from BioMarin, Chiesi and Sanofi. Consultant fees from Relay Therapeutics, Spark Therapeutics and uniQure. Grants/research support from Amicus Therapeutics and Takeda. Salary/contractual service fees from Prevention Genetics (spouse) and Fulgent Diagnostics (spouse; relationship ended). Other financial or material support (principal/sub investigator fees for sponsored clinical studies) from 4D Molecular Therapeutics, Alexion, Amicus Therapeutics, BioMarin, Chiesi, Cyclo Therapeutics, Denali Therapeutics, Sangamo, Sanofi and Takeda.
